This is a question about interpretation, not about whether to act — I will take action questions elsewhere.
The empirical answer seems settled. The explanation does not.
If the honest answer is that nobody knows, I would rather hear that than a plausible story.
Why does this happen, and what would falsify the usual explanation?
Start with the difference between thyroid function and thyroid structure. Function tests and the medullary-carcinoma question are entirely separate topics that share a word.
Incidental thyroid nodules are extremely common in the general population, so a nodule found after starting a drug is far more likely to be a nodule that was found than a nodule that was caused.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Concretely, rodent studies showed dose- and duration-dependent C-cell hyperplasia and medullary thyroid tumours with GLP-1 receptor agonists. Human C cells express the receptor at far lower density, and the effect has not been reproduced in human data across a decade of exposure.
Human epidemiological studies looking for a medullary thyroid carcinoma signal have not found a consistent association, and the base rate of the tumour is low enough that detecting a small effect would need very large cohorts.
Spontaneous adverse-event reports are not incidence data and should never be quoted as though they were.
Do not monitor calcitonin routinely; the guidance against it is well reasoned.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe short version: no consistent effect on thyroid function tests, a species-specific preclinical signal for C-cell tumours, and a contraindication written to be cautious about it.
Reference intervals for thyroid-stimulating hormone are wide, typically about 0.4 to 4.0 milli-international units per litre, and the diurnal swing within a day is a few tenths.
More usefully, pharmacovigilance databases show reports in this area, as they do for every widely used drug, and disproportionality signals from spontaneous reporting are hypothesis-generating rather than evidence of causation.
The caveat is that a family history of medullary thyroid carcinoma or MEN2 is a genuine contraindication and is not something to reason around on a forum.
Rodent C-cell density is the crux of the translation argument, and it is worth knowing once.
Answering this needs the distinction between medullary thyroid carcinoma, which arises from calcitonin-producing C cells, and the far more common papillary and follicular cancers, which do not.
Thyroid function tests do not change consistently in this class. Where a shift appears, weight change and altered thyroxine absorption are more parsimonious explanations than a direct effect.
Mechanically, levothyroxine absorption can be affected by delayed gastric emptying, so someone on replacement who starts one of these agents has a plausible reason for their dose requirement to shift slightly.
Nodules are common. Finding one after starting something is usually a screening effect.
edited 30 Aug 2025 by marta_okonkwo — corrected a unit error in the worked example
Mechanically, this question comes up constantly and the answer has not changed: precautionary contraindication, no confirmed human signal, and a family history is the thing that actually matters.
The contraindication is for personal or family history of medullary thyroid carcinoma and for multiple endocrine neoplasia type 2. It is not a contraindication for thyroid disease generally, and the two get conflated constantly.
Nothing here is medical advice. Anyone on thyroid hormone replacement should have that managed by a clinician who knows what else they are taking.
Family history of medullary carcinoma or MEN2 is the question that matters. General thyroid disease is a different topic.
Thyroid-stimulating hormone has a wide reference interval and a diurnal swing, so small changes within the interval are not evidence of anything.
Routine calcitonin monitoring is explicitly not recommended, because its specificity at the relevant thresholds is poor enough that it generates more unnecessary investigation than it prevents.
Guidance against routine calcitonin screening rests on its performance characteristics in unselected populations rather than on any claim that the concern is unfounded.
If you take levothyroxine, the absorption question is worth raising with whoever prescribes it.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.